Gesynta Pharma is focused on developing innovative pharmaceuticals that target inflammation and pain, particularly in chronic conditions such as endometriosis. Their lead drug candidate, Vipoglanstat (GS-248), is currently in clinical phase II development and operates through a unique mechanism of action by selectively inhibiting the enzyme microsomal prostaglandin E synthase-1 (mPGES-1). This inhibition reduces the production of prostaglandin E2 (PGE2), a key inflammatory mediator, thereby alleviating pain and inflammation associated with endometriosis. Preclinical studies have shown that Vipoglanstat significantly decreases endometrial lesions and improves pain-related outcomes, supporting its potential as a disease-modifying treatment.

In addition to Vipoglanstat, Gesynta Pharma is advancing another drug candidate, GS-073, which also targets mPGES-1 and is poised to enter clinical phase I for chronic inflammatory pain. Both drug candidates are designed to provide more precise anti-inflammatory effects compared to existing treatments, addressing a significant medical need in their respective therapeutic areas. The company has established a solid scientific foundation for these candidates, backed by favorable safety profiles and pharmacokinetic properties observed in previous studies, which positions them well for further clinical development.

Sweden

Drug candidates with a unique mechanism of action, aiming to reduce inflammation and pain. Vipoglanstat to enter phase II for endometriosis.

Gesynta Pharma

Company Details